Skip to main content
Explore URMC

menu

Pancreatic Cancer: A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma (CanStem111P)

Research Question:
Will patients with pancreatic cancer have a longer cancer free survival when receiving treatment with nab-Paclitaxel and Gemcitabine with the study drug, BBI-608, versus treatment with nab-Paclitaxel and Gemcitabine alone?

Basic Study Information

Purpose:
There will be two study groups: Group 1 (EXPERIMENTAL TREATMENT): Nab-Paclitaxel with Gemcitabine plus BBI-608 and Group 2: (NON-EXPERIMENTAL TREATMENT): Nab-Paclitaxel with Gemcitabine. Researchers are hoping to learn if patients will have a longer cancer free survival when receiving a standard chemotherapy regimen with the study drug, BBI-608 versus standard chemotherapy regimen alone.

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT02993731?term=CanStem111P&rank=1
Study Reference #: IGIP17029

Lead Researcher (Principal Investigator)

Lead Researcher: Marcus Noel

Study Contact Information

Study Coordinator: Kari Steinmetz
Phone: (585) 276-4447
Email: Kari_Steinmetz@urmc.rochester.edu

Additional Study Details

Learn More About These Conditions

More information about Pancreatic Cancer

Return to Search